Advanced search
Publication Cover
Pediatric Hematology and Oncology Volume 41, 2024 - Issue 3
Submit an article Journal homepage
72
Views
0
CrossRef citations to date
0
Altmetric
Brief Reports

Cost and effectiveness comparison of sirolimus versus standard treatment in Kasabach-Merritt phenomenon: a real-world evidence study in Thailand

Chanikarn Tongruanga Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, ThailandView further author information
,
Siriwan Wananukulb Division of Dermatology, Department of Pediatrics, Faculty of Medicine King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, ThailandView further author information
,
Susheera Chatproedpraib Division of Dermatology, Department of Pediatrics, Faculty of Medicine King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, ThailandView further author information
,
Nattee Narkbunnamc Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandView further author information
,
Rattanavalai Nitiyaromd Division of Dermatology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandView further author information
,
Nongnuch Sirachainane Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, ThailandView further author information
,
Rungrote Natesirinilkulf Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine Chiang Mai University Hospital, Chiang Mai University, Chiang Mai, ThailandView further author information
,
Phumin Chaweephisalg The Integrative and Innovative Hematology/Oncology Research Unit, Faculty of Medicine Chulalongkorn University, Bangkok, ThailandView further author information
&
Darintr Sosothikula Division of Hematology and Oncology, Department of Pediatrics, Faculty of Medicine King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand;g The Integrative and Innovative Hematology/Oncology Research Unit, Faculty of Medicine Chulalongkorn University, Bangkok, ThailandCorrespondence[email protected] [email protected]
View further author information
 show all
Pages 229-239 | Received 03 Oct 2023, Accepted 18 Dec 2023, Published online: 18 Jan 2024

References

  • Mahajan P, Margolin J, Iacobas I. Kasabach-Merritt phenomenon: classic presentation and management options. Clin Med Insights Blood Disord. 2017;10:1179545X17699849. doi:10.1177/1179545X17699849.
  • Ji Y, Chen S, Xiang B, et al. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: a multicenter retrospective study. Int J Cancer. 2017;141(4):848–855. doi:10.1002/ijc.30775.
  • Blatt J, Stavas J, Moats-Staats B, Woosley J, Morrell DS. Treatment of childhood kaposiform hemangioendothelioma with sirolimus. Pediatr Blood Cancer. 2010;55(7):1396–1398. doi:10.1002/pbc.22766.
  • Zhang L, Liu L, Luo H, et al. Combination therapy for pediatric patients with Kasabach-Merritt phenomenon: a single-center retrospective study. Medicine (Baltimore). 2022;101(34):e30296.). doi:10.1097/MD.0000000000030296.
  • Hammill AM, Wentzel M, Gupta A, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer. 2011;57(6):1018–1024. doi:10.1002/pbc.23124.
  • Wang H, Duan Y, Gao Y, Guo X. Sirolimus for vincristine-resistant Kasabach-Merritt phenomenon: report of eight patients. Pediatr Dermatol. 2017;34(3):261–265. doi:10.1111/pde.13077.
  • Freixo C, Ferreira V, Martins J, et al. Efficacy and safety of sirolimus in the treatment of vascular anomalies: a systematic review. J Vasc Surg. 2020;71(1):318–327. doi:10.1016/j.jvs.2019.06.217.
  • Tan X, Zhang J, Zhou S, Liu Z, Zhang T, Xia J. Successful management of steroid-resistant vascular tumors associated with the Kasabach-Merritt phenomenon using sirolimus. J Dermatol. 2018;45(5):580–583. doi:10.1111/1346-8138.14231.
  • Karastaneva A, Gasparella P, Tschauner S, et al. Indications and limitations of sirolimus in the treatment of vascular anomalies-insights from a retrospective case series. Front Pediatr. 2022;10:857436. doi:10.3389/fped.2022.857436.
  • Wang Z, Yao W, Sun H, et al. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up. J Dermatol. 2019;46(11):956–961. doi:10.1111/1346-8138.15076.
  • Harbers VEM, van der Salm N, Pegge SAH, et al. Effective low-dose sirolimus regimen for kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon in young infants. Br J Clin Pharmacol. 2022;88(6):2769–2781. doi:10.1111/bcp.15202.
  • Wang Z, Li K, Dong K, Xiao X, Zheng S. Refractory Kasabach-Merritt phenomenon successfully treated with sirolimus, and a mini-review of the published work. J Dermatol. 2015;42(4):401–404. doi:10.1111/1346-8138.12797.
  • Jahnel J, Lackner H, Reiterer F, Urlesberger B, Urban C. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus. Klin Padiatr. 2012;224(6):395–397. doi:10.1055/s-0032-1323823.
  • Wang Z, Li K, Dong K, Xiao X, Zheng S. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus. J Pediatr Hematol Oncol. 2015;37(1):72–73. doi:10.1097/MPH.0000000000000068.
  • Mariani LG, Schmitt IR, Garcia CD, Kiszewski AE. Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon. Pediatr Blood Cancer. 2019;66(8):e27810. doi:10.1002/pbc.27810.
  • Kai L, Wang Z, Yao W, Dong K, Xiao X. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma. J Cancer Res Clin Oncol. 2014;140(3):471–476. doi:10.1007/s00432-013-1549-3.
  • Wang H, Guo X, Duan Y, Zheng B, Gao Y. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma. Pediatr Dermatol. 2018;35(5):635–638. doi:10.1111/pde.13600.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.